Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer.
Claudio Zamagni
No relevant relationships to disclose
Myriam Perrone
No relevant relationships to disclose
Vincenzo Dario Mandato
No relevant relationships to disclose
Alessandra Bologna
No relevant relationships to disclose
Daniela Rubino
No relevant relationships to disclose
Giorgia Zucchini
No relevant relationships to disclose
Nuria Maria Asensio Sierra
No relevant relationships to disclose
Elena Barbieri
No relevant relationships to disclose
Marta Cubelli
No relevant relationships to disclose
Pierandrea De Iaco
No relevant relationships to disclose
Martino Abrate
No relevant relationships to disclose